Resveratrol showed anti-inflammatory effects on hippocampus via suppressing NFκB.

BACKGROUND: Traumatic brain injury (TBI) is the damage to the brain caused by external blow or jolt to the head or body. TBI secondarily induces cell damage in the hippocampus. This study aimed to investigate effects of resveratrol treatment histological examination and nuclear factor kappa B (NFκB) expression in hippocampus after TBI. MATERIALS AND METHODS: Twenty-four rats were assigned to three groups: sham, TBI and TBI+Resveratol. TBI was conducted by dropping a 50-g weight from a 1-meter height from a tube to the head of animals. 20 mg/kg resveratrol was orally administered to rats after TBI. Blood was collected to measure malondialdehyde (MDA) and glutathione (GSH) contents. Cerebral tissues were processed for histopathology and furtherly for immunohistochemical analysis. RESULTS: MDA content was significantly increased and GSH value were significantly decreased in TBI group compared to sham group. Resveratrol treatment significantly improved biochemical scores in TBI+Resveratrol group. Normal histological appearance was observed in hippocampal sections of sham group. In TBI group, neurons in hippocampus were degenerated. Their nuclei were pyknotic. Other neurons and supportive neuroglial cells in hippocampal proper and dentate gyrus were also disrupted. Hippocampal proper integrity was lost with vascular dilatation. NFκB was upregulated in hippocampal neurons of TBI group. CONCLUSIONS: Resveratrol treatment alleviated pathologies and downregulated NFκB expression in hippocampus. TBI caused adverse alterations in free radicals' balance system and histological structures of hippocampus. Resveratrol with its antioxidant and anti-inflammatory effects reduced the damage caused by TBI.

Comparison of ependymomas and medulloblastomas located in the posterior cranial fossa: An anatomical and histopathological study.

Posterior fossa tumors (PFTs) include medulloblastomas, atypical teratoid/rhabdoid tumors, pilocytic astrocytomas, ependymomas, and brainstem gliomas. We evaluated patients with surgery at our clinic, comparing epidemiological, clinical, radiological, and pathological characteristics of medulloblastoma and ependymoma to identify factors that might assist preoperative diagnosis, help to develop treatment algorithms, and have prognostic value after surgery. Pediatric patients from 0 to 16 and young adults from 16 to 29 years of age with surgery for pathologically confirmed ependymomas or medulloblastomas between January 2014 and January 2020 were eligible. The study included 19 patients, seven with ependymoma (37%) and 12 with medulloblastoma (63.2%). The ependymoma patients were 5.29 ± 5.85 years of age, the medulloblastoma patients were 11.58 ± 8.17 years of age, and 16 patients (84%) were children.Fifteen patients (79%) presented with signs of increased intracranial pressure and four (21%) presented with cerebellar findings. MRI found that 74% (14) of the PSTs were located in the midline, including six of the seven ependymomas (86%) and eight of the 12 medulloblastomas (67%). Enhancement was significantly greater in medulloblastomas compared with ependymomas (p = 0.022). In according to pathology results; synaptophysin, NSE, chromogranin and 50% GFAP positivity were observed in medulloblastoma. Ependymomas were S100 (43%) and vimentin (29%) positive. Ependymoma patients were younger than medulloblastoma patients and more were female. There were no significant differences in the clinical findings, but ependymomas were larger and had greater rates of enhancement and spinal metastasis compared with medulloblastomas.